Words cannot express the joy I feel as an #oncologist, knowing that my patient not only overcame stage 4 #ColorectalCancer but also became a mother to a beautiful baby girl whom she named after me. It's an incredible honor to be part of her journey. #miraclesdohappen#MedTwitter
Yes he played a huge part and also was very open about the awful skin rash he developed. The doctors leading this work, the charities and @RevMedicines have also very been proactive, supporting treatment algorithms with us at @OpenMedInsights Impressive they have ‘owned the toxicity and been so proactive in addressing it. And a great group of people. We could all learn a lot from them. Time we manage toxicities more proactively and aggressively.
@OpenMedInsights@drallysonocean@DrShubhamPant@GIMedOnc@DrDanielKing@MPishvaian@GIMedOnc and many more.
Would you like a glimpse of the future? Where solid tumor oncology may be heading?
Look no further.
Agenus may have had some ups and downs in the past (BATMAN -> ROBBIN), but Bot Bal looks like it has the capacity to absolutely change how we manage MSS solid tumors.
UNICORN, now in Nature Medicine. Phase 2, non-randomized, window-of-opportunity. Resectable rT3-4 colon cancer. One dose of botensilimab, two doses of balstilimab, surgery around day 30-40.
Highlights:
MPR 36% (5/14) in MSS disease, pCR 29%. Omg. (compare to FOLFOX in FOxTROT: 8%)
Bot alone in MSS: 0%. The PD-1 matters.
dMMR Bot Bal: MPR 100%, pCR 93%
😍12-month EFS 100% in both Bot Bal cohorts
Yes there is tox. irAEs in 54%, mostly flu-like symptoms, and only one grade 3 (hyperthyroidism). No grade 3 diarrhea.
Every MSS responder cleared ctDNA before surgery, that’s a helpful tool for predicting response in a disease that may fibrose and stay visible on imaging.
The holy grail is almost here: melting the majority of rectal cancers away. In MSI-H we have AZUR-1. In MSS, perhaps we have this in the future.
nature.com/articles/s41591-0…@OncoAlert@TheGutOncLab@Onco_Nexus
Thank you @AlbertBourla for your inspiring words at #PrixGalien “Great things are accomplished by optimists who challenge the common wisdom” @Pfizer lives up to these words with a Phase 3 study of ponsegromab for cancer cachexia. The common wisdom in oncology is focused solely on shrinking tumors, but @EdReznik showed that cachexia triples the risk of death in cancer, so blocking it, at the optimistic extreme, could one day help keep cancer patients alive for decades. At @Immuneering$IMRX we may have the only other Phase 3 program designed to counteract cancer cachexia (through a distinct and complementary mechanism to ponsegromab) while also shrinking tumors: #atebimetinib. Keeping aiming for great things Albert and team … and so will we!
Every company developing G12X drugs should pay attention to this data at #ESMO26
Zecdarasib (G12Di) plus chemo in 1L metastatic PDAC, phase 1
ORR 89% with mFOLFIRINOX (n=27) ORR 69% with gem/nab-paclitaxel (n=26)
Awesome safety for early DE.
For context, other early 1L PDAC response rates (cross-trial which we would neeeeever do):
Zoldonrasib + FOLFIRINOX: 82% Zoldonrasib + gem/nab-P: 61% Daraxonrasib + gem/nab-P: 59% Daraxonrasib alone: 47%
Chemo clearly still matters. Starting to think about this like Breakwater…
In PDAC, monoallelic inhibitors are extremely effective, just more effective with a little extra oomph behind them.
They will land in adjuvant, neoadjuvant, metastatic and every space you can imagine in the next few years.
Question is do we combo single plus pan or single plus chemo, and what is the added agent (especially in CRC)?
@OncoAlert@TheGutOncLab@Onco_Nexus@Incyte
Full-circle moment in España! 🇪🇸
In 1992, I studied abroad in Madrid while @TuftsUniversity.
In 1998, I returned to Barcelona during @TuftsMedSchool.
I still remember doctors smoking on rounds, the entire hospital seemingly disappearing for lunch (who was taking care of the patients?!), & everything being autoclaved & reused. Nothing disposable.
Nearly 30 years later, I’m back in Madrid for #ESMO26, reflecting on just how much medicine has changed.
We’ve gone from an era dominated by chemotherapy to precision oncology, targeted therapies, & #immunotherapy. And now we’re envisioning a future where we can treat GI cancers
WITHOUT SURGERY,
WITHOUT CHEMOTHERAPY
& WITH IMMUNOTHERAPY
& NOT just patients with MSI-high tumors.
In #pancreaticcancer, progress has often felt painfully slow, but the breakthroughs we’re witnessing today give me more hope than ever.
Spain holds such special memories for me. What a privilege to return, reflect on how far we’ve come, and be part of what comes next.
Same city. Different chapter. A whole new era of cancer care. ❤️
#Oncology#PrecisionMedicine
Always fun catching up with @CKavovit from @Medscape. We chatted about #ESMO26, the exciting science, and why I love Medscape’s conference coverage. With so much happening at these meetings, I really appreciate the expert perspectives, key highlights, and the chance to catch up on what I missed.
Thanks, Caryn, for a great conversation!
HARMONi-GI1, presidential session at #ESMO26.
@UGrewalMD guessed .7 HR I guessed .8 HR We were equally right (.75 HR).
Phase 3, 1L advanced biliary tract cancer: ivonescimab (PD-1 x VEGF) + GemCis vs durvalumab + GemCis. 682 patients, median follow-up 14.3 mo.
OS 14.9 vs 12.1 mo, HR 0.75 (95% CI 0.61-0.92), p=0.0031
PFS 8.4 vs 5.8 mo, HR 0.61 (95% CI 0.51-0.72)
ORR 53.8% vs 32.5%
This was an appropriate comparator for 2026 and compelling data (although really did need every one of those patients to power).
Probable new first line once the full data comes out.
The bispecifics era is in full force.
@OncoAlert@TheGutOncLab@UGrewalMD@Onco_Nexus
While oncologists gather at #ESMO26 to learn about breakthroughs in #cancer treatment, our patients are home coping with the side effects.
💙 That’s why Oceans of Blessings provides Blessings Bags filled with safe, non-toxic skincare to soothe their skin and lift their spirits.
🌊 oceansofblessings.com
📸 Instagram: @oceansofblessings
𝕏: @OceansBlessings#OceansOfBlessings#CancerCare#ESMO26
It was a great honour to present the results of the phase 3 INTerpath-001 clinical trial at the #ESMO26 Congress in Madrid.
This international trial included 1137 patients, across 157 sites, whose melanoma had been surgically removed, but who were at very high risk of it returning. The trial showed adding #intismeran autogene, an mRNA based individualised neoantigen therapy, to pembrolizumab reduced the risk of recurrence or death by 42%.
This is the first phase 3 study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumour can reduce the risk of recurrence or death from cancer. That fingerprint is read by sequencing the tumour, then a ‘wanted poster’ of the cancer is made as mRNA, showing the immune system exactly what to look for and attack. Having succeeded in melanoma, this proof of concept could mark the beginning of a foundational shift in how we treat cancer.
Read more >melanoma.org.au/news/persona…
A huge thank you to all patients and teams involved.
@myESMO@Sydney_Uni@syd_health@Science_Academy@AAHMS_health@FulbrightAUS@NthSydHealth@ausoftheyear
#ESMO26 starts tomorrow! @TimothyJBrownMD@UGrewalMD and I went through the GI abstracts we think are most likely to change practice by Monday. If you're looking for a quick listen to orient yourself to what is coming in the next few days for GI Oncology (it is ALOT) give it a listen and lets see if our predictions pan out.
@OncoAlert@Onco_Nexus@TheGutOncLabopen.spotify.com/episode/4HP…